Embody, Inc.
2023
$155M
Zimmer Biomet
Medical Devices & Healthcare TechnologyFounded 1927- HQ today: Warsaw, Indiana, United States
Reviewed by Swet Parvadiya
Company data updated: November 2026
Acquisitions
Zimmer Biomet Acquisitions
4
Major Deals Covered
$16.9B
Disclosed Deal Value
What are Zimmer Biomet's biggest acquisitions?
Zimmer Biomet's largest disclosed acquisition here is Embody, Inc. for $155 in 2023. This page covers 4 major deals from 2003 to 2023, each with its price where disclosed and the reason behind it.
- Major deals covered
- 4
- Largest deal
- Embody, Inc. ($155)
- First deal
- 2003
- Most recent
- 2023
| Company | Year | Price | Purpose |
|---|---|---|---|
| 2015 | Undisclosed | Transformative mega-merger uniting two premier global orthopedic implant portfolios. | |
| 2016 | Undisclosed | French robotics pioneer providing core architecture for the ROSA robotic surgery platform. | |
| 2003 | Undisclosed | Swiss medical device manufacturer expanding European orthopedic and dental distribution. | |
| 2023 | Undisclosed | Microengineered collagen implants for tendon and ligament soft-tissue repair. |
- What companies has Zimmer Biomet bought?
- Major acquisitions by Zimmer Biomet documented here include Embody, Inc. (2023), Medtech SA (2016), Biomet, Inc. (2015) and Centerpulse AG (2003).
- What is Zimmer Biomet's most recent acquisition?
- The most recent Zimmer Biomet acquisition documented here is Embody, Inc., in 2023, for $155.
Medtech SA
2016
$132M
Biomet, Inc.
2015
$13.4B
Centerpulse AG
2003
$3.2B
Zimmer Biomet's Growth & Acquisition Strategy
Under CEO Ivan Tornos, Zimmer Biomet is executing four core growth initiatives: (1) Scaling ROSA Robotic Placements in ASCs: Driving rapid commercial placement of ROSA Knee and Hip systems in Ambulatory Surgery Centers, where outpatient joint replacement procedures are expanding at double-digit rates; (2) Expanding Smart Implant Ecosystems: Developing next-generation Persona IQ applications for hip reconstruction and shoulder arthroplasty to expand smart orthopedic monitoring; (3) Accelerating SET & Sports Medicine Portfolio: Investing in high-margin soft tissue repair, collagen matrix grafts (Embody), and reverse shoulder prostheses; and (4) International Commercial Expansion: Expanding direct commercial sales teams and localized surgeon education programs across Japan, China, India, and Latin America.
How Zimmer Biomet Makes Money
Zimmer Biomet operates a high-margin medical device business model built on surgical implants, robotic capital systems, and recurring procedural consumables: (1) Knees (~$2.9B revenue), generating steady high-margin cash flows from primary, partial, and revision knee reconstruction implants (Persona, NexGen, Oxford); (2) Hips (~$2.1B revenue), monetizing femoral stems, acetabular cups, and ceramic bearing surfaces (Avenir Complete, G7 Dual Mobility); (3) SET (Sports Medicine, Extremities, Trauma) (~$1.8B revenue), providing arthroscopic soft tissue repair, reverse shoulder implants, and fracture fixation hardware; and (4) Surgical & Robotic Technologies (~$0.9B revenue), placing ROSA robotic consoles in hospital operating rooms and outpatient surgery centers, driving compulsory long-term adoption of proprietary Zimmer Biomet joint implants. The company maintains gross margins near 71% and generates over $1.5 billion in annual operating cash flow.
Zimmer Biomet Acquisitions FAQ
What is Zimmer Biomet's general approach to M&A and acquisitions?
Zimmer Biomet pursues a disciplined, strategic M&A approach focused on acquiring proprietary technologies, expanding customer distribution reach, and unlocking operational cost synergies rather than pursuing unselective scale.
What were some of the most transformative acquisitions completed by Zimmer Biomet?
Transformative transactions in Zimmer Biomet's history include pivotal mergers and acquisitions that secured key regional footprints, consolidated core market share, and brought proprietary software intellectual property in-house.
How does Zimmer Biomet successfully integrate acquired companies?
Zimmer Biomet deploys dedicated integration teams to harmonize core software stacks, align regulatory compliance systems, and unite company cultures while preserving entrepreneurial agility.
Does Zimmer Biomet divest non-core corporate assets?
Yes, Zimmer Biomet periodically evaluates its corporate portfolio, strategically divesting non-core or non-strategic assets to redeploy capital into high-margin core operational divisions.
Related M&A Histories
Compare corporate acquisition records, deal values, and strategic targets
Explore Zimmer Biomet
Core profile pages, founders and related research hubs for this company.